Company Focuses on Commitment to Blood Banking, Transfusion Medicine and Cellular Therapies
LAKEWOOD, Colo. - Monday, April 2nd 2012 [ME NewsWire]
(BUSINESS WIRE)-- CaridianBCT and Terumo Transfusion have become Terumo
BCT. Terumo BCT is one of the largest, U.S.-based medical device
companies focused on blood banking, transfusion medicine and cellular
therapies.
Terumo BCT, a subsidiary of Terumo Corporation, is headquartered in
Lakewood, Colorado. President and CEO of CaridianBCT, David Perez,
retains his position, serving as Terumo BCT’s President and CEO. Perez
was also named Chairman of Terumo Corporation’s Blood Management
Division on May 22, 2011.
Key Facts:
Terumo BCT was established through the integration of CaridianBCT
and Terumo Transfusion, following Terumo Corporation’s acquisitionof
CaridianBCT in April 2011.
Terumo BCT, headquartered in Lakewood, Colorado, is the only Terumo
Corporation subsidiary with its global headquarters located outside of
Japan.
Terumo BCT has 2,500 associates and customers in more than 120
countries and territories, with regional headquarters in Brussels,
Buenos Aires, Hong Kong and Tokyo.
Terumo BCT serves three primary customer segments: Blood Centers,
Hospitals & Therapeutic Apheresis Centers and Biotech & Cell
Processing.
Key Quotes:
David Perez, President and CEO, Terumo BCT, and Chairman, Terumo Corporation Blood Management Division
“By listening to our customers and collaborating closely with them, we
have the opportunity to unlock the potential of blood to make even
safer, higher-quality transfusions available to more people around the
world; to help blood centers operate at an even higher level of
productivity; to enable an ever-wider range of diseases to be treated
with blood therapies; and to help researchers develop cellular therapies
that could fundamentally improve health care. The bottom line is that
Terumo BCT has the potential to not only help our customers but to
improve patient outcomes.
“This is an exciting moment for both companies. We have united two
industry leaders, both strongly focused on customers and the patients we
ultimately serve, with similar cultures and value systems. Both
organizations, now Terumo BCT, share a passion for developing and
delivering innovation to our global customers, and a commitment to
quality and delighting our customers through continuous improvement in
all we do.”
Key Resources:
Terumo BCT Company Fact Sheet
Terumo BCT About Us Presentation
Terumo BCT Product Fact Sheet
Terumo BCT Executive Leadership
About Terumo BCT:
Terumo BCT, a global leader in blood component and cellular
technologies, is the only company with the unique combination of
apheresis collections, manual and automated whole blood processing, and
pathogen reduction coupled with leading technologies in therapeutic
apheresis and cell processing. We believe in the potential of blood to
do even more for patients than it does today. This belief inspires our
innovation and strengthens our collaboration with customers.
About Terumo Corporation:
Tokyo-based Terumo Corporation is one of the world’s leading medical
device manufacturers with operations in more than 160 nations. Founded
in 1921, the company develops, manufactures and distributes world-class
medical devices including products for use in cardiothoracic surgery,
interventional procedures and transfusion medicine; the company also
manufactures a broad array of syringe and hypodermic needle products for
hospital and physician office use. Terumo contributes to society by
providing valued products and services to the health care market and by
responding to the needs of health care providers and the people they
serve. Terumo Corporation’s shares are listed on the first section of
the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or
Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan’s
leading stock index.
Contacts
Terumo BCT
Laura Fusco
Global Corporate Communications
Phone: +1.303.205.2546
press@caridianbct.com
No comments:
Post a Comment